Metsera Tumbles After Novo Pulls Out of Bidding War With Pfizer

Pfizer Inc. has successfully acquired Metsera Inc., a developer of an experimental weight-loss drug, for $65.60 per share in cash plus up to $20.65 per share in milestone payments, after Novo Nordisk A/S withdrew its competing bid. Metsera shares tumbled up to 16% in premarket trading following Novo's exit, which was prompted by Pfizer matching its offer and US FTC regulatory concerns. This deal secures Pfizer's entry into the lucrative obesity market, while Novo Nordisk will now focus on its internal pipeline, including a pill version of Wegovy, and other strategic opportunities in diabetes and obesity.

Analysis

Pfizer Inc. has successfully acquired Metsera Inc. for $65.60 per share in cash, plus up to $20.65 per share in milestone payments, after Novo Nordisk A/S withdrew its competing bid. Metsera shares (MTSR) consequently slumped 16% to $70.12 in premarket trading, erasing some gains since its January IPO. This deal secures Pfizer's entry into the competitive obesity drug market.

Novo Nordisk's withdrawal was driven by Pfizer matching its offer and US Federal Trade Commission concerns regarding potential regulatory risks. Despite significant deal capacity, Novo viewed Metsera as a "bolt-on" acquisition. The company will now refocus on its internal pipeline, including upcoming Alzheimer's clinical trial results and the planned launch of a pill version of Wegovy.

Pfizer's stock (PFE) rose 1% premarket, reflecting positive investor sentiment for its strategic entry into the lucrative obesity market. Novo's shares (NVO) also rose 3.8% in Copenhagen, suggesting investor relief or renewed focus on its core pipeline, despite a 52% year-to-date decline. The FTC's intervention signals increasing regulatory scrutiny in large pharmaceutical M&A.

Key Decisions for Investors

• Investors in Pfizer should monitor the integration of Metsera and its pipeline development as a key driver for future growth in the obesity market
• Novo Nordisk investors should focus on upcoming clinical trial results and the Wegovy pill launch as primary value catalysts following the acquisition withdrawal
• The Metsera share price decline post-bid withdrawal serves as a reminder of M&A premium volatility for early-stage assets
• Broader market participants should note the increasing regulatory scrutiny in pharmaceutical M&A as a potential factor in future deal assessments